Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
[Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome].
OBJECTIVES To evaluate the effects of combined atorvastatin and probucol use on endothelial function in patients with acute coronary syndrome ( ACS ) . METHODS Thirty patients with ACS were r and omized to receive atorvastatin ( 20 mg/d ) and probucol ( 500 mg/d , combination group , n = 15 ) or atorvastatin ( 20 mg/d ) alone ( atorvastatin group ) within 24 h after admission for 4 weeks . Endothelium-dependent flow-mediated dilatation ( FMD ) and endothelium-independent sublingual nitroglycerin-mediated dilatation ( NMD ) as well as the levels of lipids and C-reactive protein were assessed at baseline , 1 week and 4 weeks after therapy . RESULTS Compared to baseline , the levels of total cholesterol , LDL-C and C-reactive protein were significantly reduced after 1 week and 4 weeks in both groups , FMD equally increased after 1 week in both groups ( atorvastatin group : 3.75 % + /- 0.78 % vs. 1.09 % + /- 0.44 % , combination group : 3.67 % + /- 0.36 % vs. 1.24 % + /- 0.37 % , P < 0.01 ) . Post 4 weeks therapy , FMD increase was significantly higher in combination group ( 3.67 % + /- 0.36 % at 1 week vs. 6.85 % + /- 0.64 % at 4 weeks , P < 0.01 ) than that in atorvastatin group ( 3.75 % + /- 0.78 % vs. 3.80 % + /- 0.31 % , P = 0.954 ) . NMD also equally and increased over 4 weeks in two groups ( P < 0.01 vs. baseline ) . There was no correlation between the change in FMD/NMD and the changes in lipids or C-reactive protein levels . CONCLUSIONS The combined atorvastatin and probucol therapy early after ACS is superior to atorvastatin alone on improving endothelial function
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .